Genezen
Viral Vectors for Cell & Gene Therapy / Plasmid Manufacturing / Testing – CDMO
Goals & Objectives
Genezen is a CDMO offering development and manufacturing of viral vectors for gene therapies and various cell therapies. Investment from Ampersand Capital Partners had expanded facilities and capabilities from legacy expertise in Lentivirus and Retroviral vectors to the addition of AAVs.
Strategic Approach
Genezen had potential to realize its expansion through M&A or organic growth. We built a strategy that would accommodate either direction. As a company that had been in advanced therapies for over a decade, Genezen is not a bandwagon entry, so messaging focused on connecting audiences with its depth of experience.
Meeting & Exceeding KPIs
The new brand for Genezen brought a very memorable appearance to the business, promoting recognition and positioning it as a leader in viral vectors for gene and cell therapies. This laid a strong foundation to achieve growth in sales.
